Clinical Trials Browser

Phase 2 × Patient Preference × Nivolumab × Clear all

NCT06101134 2026-04-09

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Phase 2 Active not recruiting

100 enrolled 11 charts

Melanoma, Neoplasm Metastasis, Patient Preference